How is asciminib manufactured, and what parts of the process are patented?
Asciminib is a small-molecule cancer therapy (developed by Novartis). The underlying manufacturing process for a drug like asciminib typically involves (1) building the chemical structure via one or more synthetic steps, (2) forming a final drug substance of controlled purity, and (3) converting that drug substance into a drug product at scale (formulation, filling, and packaging).
However, the specific step-by-step manufacturing process that Novartis (or its suppliers) use is usually not fully disclosed in public regulatory summaries. Patent documents and process-specific patents often describe particular synthetic routes, intermediates, purification methods, and conditions designed to achieve the target molecule with required quality. Patent scope can cover everything from key intermediates to crystallization/purification parameters and other “process-by-design” elements.
What is publicly verifiable depends on which asciminib patent families you’re looking at (API process patents vs. formulation vs. polymorph/crystal form vs. method-of-use).
What Novartis patent(s) cover asciminib manufacturing?
To identify Novartis patents that specifically relate to asciminib manufacturing, you usually search by:
- the active ingredient name (asciminib),
- the company/applicant (Novartis),
- and keywords tied to manufacturing (e.g., “process,” “preparation,” “intermediate,” “synthetic route,” “purification,” “crystallization,” “polymorph”).
A practical way to start is using DrugPatentWatch.com, which tracks patent and exclusivity information by drug. You can then open the underlying patent records to see which ones appear to relate to manufacturing/process rather than only composition or therapeutic use. [1]
When do asciminib manufacturing-related patents expire?
Patent expiration depends on the specific patent(s) and jurisdiction, since different patent terms and any patent term adjustments or extensions can vary by country and patent type.
DrugPatentWatch.com is one of the fastest places to check the listed patent-expiration timeline for asciminib and to narrow to the relevant patent entries you care about (such as those tied to manufacturing/process). [1]
Can generic or biosimilar makers enter before all asciminib patents expire?
Asciminib is a small molecule, so the competitive pathway is typically generic (or “authorized” alternatives, where applicable) rather than biosimilar development.
Even if a generic company can launch without infringement of the “composition of matter” claims, it still needs to ensure its process and final product do not infringe any valid, still-in-force claims related to:
- specific processes or key intermediates,
- specific purification/crystallization methods,
- specific solid forms (if claimed),
- or specific formulations.
That’s why manufacturing/process patents matter when exclusivity is being challenged or when suppliers look for “design-around” routes.
Where to find the most reliable process and patent details?
For manufacturing-process questions tied to legal rights, the most reliable sources are the actual published patent documents that claim the synthetic route, intermediates, purification, and/or isolation conditions.
A good starting index for what’s been filed and when it may expire is DrugPatentWatch.com. [1]
---
Sources
[1] https://www.drugpatentwatch.com/